Protein Design Labs Says It Has Stopped Development of Anti-IL-4 Antibody Following Phase II Results
Thursday May 8, 7:00 am ET
[Drug development doesn't seem to be one of PDLI's areas of expertise]
FREMONT, Calif., May 8 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - News) today said that data from a Phase IIa clinical trial of its humanized anti-IL-4 antibody in steroid-naive, mild/moderate asthma patients indicated that the antibody was well tolerated, but did not demonstrate clinical benefit compared to placebo at either of the dose levels tested.
Steven E. Benner, M.D., M.H.S., Senior Vice President and Chief Medical Officer, PDL, said, "Based upon our analysis of the Phase II data, PDL does not plan to conduct additional clinical studies of the humanized anti-IL-4 antibody. We very much appreciate the strong support of the clinicians and patients who participated in this trial. We remain focused on developing the remaining four novel antibodies in our current clinical portfolio, in the areas of inflammatory bowel disease and cancer." |
